

RESEARCH PAPER

NF- κ B-dependent IL-8 induction by prostaglandin E₂ receptors EP₁ and EP₄

F Neuschäfer-Rube¹, A Pathe-Neuschäfer-Rube¹, S Hippenstiel²,
M Kracht³ and GP Püschel¹

¹Institut für Ernährungswissenschaft, Universität Potsdam, Nuthetal, Germany, ²Department of
Internal Medicine/Infectious Diseases and Pulmonary Medicine, Charité – Universitätsmedizin
Berlin, Berlin, Germany, and ³Rudolf-Buchheim-Institut für Pharmakologie,
Justus-Liebig-Universität Giessen, Gießen, Germany

Correspondence

Dr F Neuschäfer-Rube, Institut
für Ernährungswissenschaft,
Universität Potsdam,
Arthur-Scheunert-Allee 114-116,
D14558 Nuthetal, Germany.
E-mail: fneusch@uni-potsdam.de

The first two authors contributed
equally to the paper.

Keywords

prostaglandin receptor; NF- κ B;
IL-8 transcription; signal
transduction

Received

16 December 2011

Revised

29 June 2012

Accepted

14 August 2012

BACKGROUND AND PURPOSE

Recent studies suggested a role for PGE₂ in the expression of the chemokine IL-8. PGE₂ signals via four different GPCRs, EP₁-EP₄. The role of EP₁ and EP₄ receptors for IL-8 induction was studied in HEK293 cells, overexpressing EP₁ (HEK-EP₁), EP₄ (HEK-EP₄) or both receptors (HEK-EP₁ + EP₄).

EXPERIMENTAL APPROACH

IL-8 mRNA and protein induction and IL-8 promoter and NF- κ B activation were assessed in EP expressing HEK cells.

KEY RESULTS

In HEK-EP₁ and HEK-EP₁ + EP₄ but not HEK or HEK-EP₄ cells, PGE₂ activated the IL-8 promoter and induced IL-8 mRNA and protein synthesis. Stimulation of HEK-EP₁ + EP₄ cells with an EP₁-specific agonist activated IL-8 promoter and induced IL-8 mRNA and protein, whereas a specific EP₄ agonist neither activated the IL-8 promoter nor induced IL-8 mRNA and protein synthesis. Simultaneous stimulation of HEK- EP₁ + EP₄ cells with both agonists activated IL-8 promoter and induced IL-8 mRNA to the same extent as PGE₂. In HEK-EP₁ + EP₄ cells, PGE₂-mediated IL-8 promoter activation and IL-8 mRNA induction were blunted by inhibition of I κ B kinase. PGE₂ activated NF- κ B in HEK-EP₁, HEK-EP₄ and HEK-EP₁ + EP₄ cells. In HEK-EP₁ + EP₄ cells, simultaneous activation of both receptors was needed for maximal PGE₂-induced NF- κ B activation. PGE₂-stimulated NF- κ B activation by EP₁ was blocked by inhibitors of PLC, calcium-signalling and Src-kinase, whereas that induced by EP₄ was only blunted by Src-kinase inhibition.

CONCLUSIONS AND IMPLICATIONS

These findings suggest that PGE₂-mediated NF- κ B activation by simultaneous stimulation of EP₁ and EP₄ receptors induces maximal IL-8 promoter activation and IL-8 mRNA and protein induction.

Abbreviations

AP-1, activator protein 1; C/EBP, CCAAT/enhancer-binding protein; CaMKII, Ca²⁺/calmodulin-dependent protein kinase II; CXCR, CXC motif chemokine receptor; EP₁₋₄, PGE₂ receptor subtype 1–4; G protein, guanine nucleotide-binding protein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IKK, I κ B kinase; InsP₃, inositol trisphosphate; MIP, macrophage inflammatory protein; PI3K, phosphoinositide 3 kinase; Wort, wortmannin

Introduction

Interleukin-8 (IL-8, CXCL8) is a 72 amino acid pro-inflammatory CXC chemokine, which is expressed in many

different cell types, including endothelial and epithelial cells as well as inflammatory cells such as monocytes, macrophages and T-cells. One of its major physiological functions is the recruitment of neutrophils from the blood to the tissue

after infection or injury. Through its function as potent chemoattractant peptide, IL-8 plays a major role in the initiation and maintenance of inflammatory responses (Harada *et al.*, 1994). In addition, IL-8 was shown to be involved in angiogenesis and tumour progression (Waugh and Wilson, 2008). In adipocytes IL-8 attenuated insulin-stimulated Akt-phosphorylation by a MAPK-dependent pathway (Kobashi *et al.*, 2009). IL-8 mediates its biological effects by binding to two different GPCRs CXCR1 and CXCR2. Both receptors signal predominantly through G α_i and pertussis toxin attenuates most IL-8 functions (Hall *et al.*, 1999).

IL-8 expression is regulated predominantly on the transcriptional level. The transcription rate is controlled by a short promoter region reaching from -11 to -133 within the 5'-flanking region of the IL-8 gene (Hoffmann *et al.*, 2002). Binding sites for the transcription factors NF- κ B, activator protein 1 (AP-1) and CCAAT/enhancer-binding protein (C/EBP) are located in this short promoter. Whereas AP-1 and C/EBP activation are not always needed for IL-8 induction, NF- κ B activation is required for IL-8 expression in nearly all cell types studied (Hoffmann *et al.*, 2002). IL-8 expression varies over a considerable range within the same cell type. In some cell types, IL-8 expression is induced more than 100-fold in response to pro-inflammatory stimuli such as TNF α and IL-1 (Roebuck, 1999; Hoffmann *et al.*, 2002). At the site of inflammation, both resident and infiltrating cells produce prostaglandins in addition to these cytokines (Rajakariar *et al.*, 2006). Experiments with non-selective COX inhibitors and COX-2-selective inhibitors have suggested that prostanoids have a role in the regulation of IL-8 synthesis. Thus, the non-specific COX-1/COX-2 inhibitor aspirin suppressed TNF α -stimulated IL-8 expression in human umbilical vein endothelial cells (Yang *et al.*, 2004). Similarly, the COX-2 inhibitor NS398 suppressed IL-8 formation in *Helicobacter pylori*-treated gastric cancer cells and inhibited IL-8 expression in bradykinin-stimulated airway epithelial cells. (Rodgers *et al.*, 2002; Takehara *et al.*, 2005). PGE₂, which is the most abundant prostaglandin at sites of inflammation, acts via binding to four specific G protein-coupled PGE₂ receptors called PGE₂ receptor subtype 1-4 (EP₁-EP₄). EP₁ is coupled to an as yet unknown G protein. Binding of PGE₂ to EP₁ leads to a transient increase in intracellular calcium concentrations (Kato *et al.*, 1995) as well as to activation of PLC presumably by coupling to a Gq protein (Ji *et al.*, 2010). EP₂ and EP₄ are coupled to Gs, and activation of these receptors leads to an increase in cAMP and activation of PKA (Breyer *et al.*, 2001). In addition, activation of EP₄ receptors but not EP₂, can stimulate phosphoinositide 3 kinase (PI3K), which subsequently leads to phosphorylation and activation of Akt kinase (Fujino *et al.*, 2003). The G protein coupling of EP₃ is more promiscuous. This receptor has different C-terminal splice variants that signal via a decrease in cAMP (Gi-coupling) and/or an increase in inositol trisphosphate (InsP₃) and Ca²⁺ (Gq-coupling).

The aim of the current study was therefore, firstly, to elucidate if PGE₂ is able to activate NF- κ B via distinct EP receptors leading to IL-8 expression and, secondly, to analyse the signal transduction pathways linking G protein-coupled EP receptors to NF- κ B activation. To this end, EP₁ and EP₄, which were shown in previous studies to be involved in PGE₂-stimulated IL-8 formation (Caristi *et al.*, 2005; Dey and

Chadee, 2008; Vij *et al.*, 2008; Dey *et al.*, 2009), were overexpressed in HEK293 cells alone or in combination. Then PGE₂ stimulated activation of the IL-8 promoter as well as IL-8 mRNA and protein induction were determined, and activation of NF- κ B in these cells was analysed. It was found that the activation of both EP₁- and EP₄-dependent signal chains by PGE₂ was needed to elicit maximal activation of the transcription factor NF- κ B, maximal IL-8 promoter activation as well as IL-8 mRNA and protein induction.

Methods

Materials

All chemicals were purchased from commercial sources indicated throughout the text. Oligonucleotides were custom-synthesized by Eurofins MWG/Operon (Ebersberg, Germany).

EP receptor specific agonists ONO-D1-004 (EP₁ agonist) and ONO-AE1-329 (EP₄ agonist) (Suzawa *et al.*, 2000) were kindly provided by ONO Pharmaceutical Co, Ltd, Osaka, Japan. Antibodies used were phospho-IKK α (Ser¹⁸⁰)/IKK β (Ser¹⁸¹), I κ B kinase (IKK) α , IKK β , phospho-Src (Tyr⁴¹⁶) and Src from cell signalling (Frankfurt, Germany).

Cell culture and treatment

HEK293 cells were cultured in DMEM containing 10% FCS and antibiotics. HEK293 cells stably expressing human EP₁ or EP₄ were established as described previously (Neuschäfer-Rube *et al.*, 2004) and maintained in HEK293 culture medium supplemented with 0.5 mg mL⁻¹ G-418 as selection marker. Double transgenic cells expressing human EP₁ and EP₄ were obtained by transfecting HEK-EP₁ cells with a pcDNA3.1-Zeo-hEP₄ expression construct. Double transgenic cell clones were selected by the addition of 0.1 mg mL⁻¹ Zeocin (CAYLA, Toulouse, France) as a second selection marker.

Cell surface ligand binding

Cells in 24-well plates (1 $\times$ 10⁵ cells per well) were washed once with a HEPES buffered salt solution (15 mM HEPES, 4.7 mM KCl, 1.2 mM KH₂PO₄, 1 mM glucose, 2.2 mM CaCl₂) and incubated for 2 h at 4°C with 100 μ L of 5 nM [³H]-PGE₂ $\pm$ 10 μ M PGE₂ to determine non-specific binding in the same buffer. To determine the contribution of EP₁ or EP₄ receptors to total [³H]-PGE₂ binding in HEK-EP₁ + EP₄ cells, 1 μ M of specific agonists were added in addition to labelled PGE₂. Plates were washed three times with ice-cold HEPES buffered salt solution and cell-associated radioactivity was released by lysing cells in 400 μ L 0.3 M NaOH containing 1% (w v⁻¹) SDS. The radioactivity in the cell lysates was counted in 5 mL Rotiszint solution (Roth, Karlsruhe, Germany).

Real-time reverse transcription (RT)-PCR

Cells were stimulated with 1 μ M PGE₂, 1 μ M of EP receptor agonists or 50 ng mL⁻¹ TNF α for the time indicated and washed with PBS. Total RNA was isolated from treated cells using GeneMatrix Universal RNA kit (EURx, Gdansk, Poland). The 1-5 μ g total RNA was reverse transcribed into cDNA using a mixture of oligo dT and random nucleotide primers and a M-MuLV reverse transcriptase (Fermentas, St. Leon Rot, Germany). Hot start real-time PCR for the quantification of

Table 1

Oligonucleotide primers for qPCR

Gene	Forward	Reverse
GAPDH	5'-TGATGACATCAAGAAGGTGG	5'-TTACTCCTTGGAGGCCATGT
IL-8	5'-CAGTTTTGCCAAGGAGTGCTAA	5'-AACTTCTCCACAACCCCTCTGC
EP ₁	5'-TCGCTTCGGCCTCCACCTTCTTTG	5'-CGTTGGGCCTCTGGTTGTGCTTAG
EP ₂	5'-CGAGACGCGACAGTGGCTTCC	5'-CGAGACGCGCGCGCTGGTAGA
EP ₃	5'-CGGGGCTACGGAGGGGATGC	5'-ATGGCGCTGGCGATGAACAACGAG
EP ₄	5'-TCGCGCAAGGAGCAGAAGGAGACG	5'-GGACGGTGGCGAGAATGAGGAAGC

Accession numbers for the genes were: GAPDH (AB062273), IL-8 (AK311874), EP₁ (L22647), EP₂ (NM_000956), EP₃ (E15918) and EP₄ (NM_000958).

each transcript was carried out using 2× Maxima SybrGreen qPCR mix (Fermentas), 0.25 µM of each primer and 2.5 µL–5 µL of cDNA that was diluted 1:10. PCR was performed with an initial enzyme activation step at 95°C for 10 min, followed by 42 cycles of denaturation at 95°C for 30 s, annealing at 57°C (GAPDH and IL-8) or 63°C (EP receptor) for 30 s and extension at 72°C for 1 min in a real-time DNA thermal cycler (iCycler™, 20 µL reaction volume or CFX96™, 10 µL reaction volume, BIO-RAD, Munich, Germany). The oligonucleotides used are listed in Table 1. The expression level was calculated as *n*-fold induction of the gene of interest (int) in treated versus control cells with GAPDH (gap) as a reference gene. The calculation is based on the differences in the threshold cycles between control (*c*) and treated (*t*) groups according to the formula: fold induction = $2^{(c - t)_{\text{int}}/2^{(c - t)_{\text{gap}}}}$. For the calculation of EP receptor copy numbers, plasmids with cloned cDNAs coding for EP receptor and GAPDH were used as a template to prepare standard curves with defined copy numbers.

IL-8 ELISA

Cells were stimulated with 1 µM PGE₂, 1 µM EP receptor agonists or 50 ng mL⁻¹ TNFα for the time indicated. After the incubation, supernatants were collected and processed for IL-8 quantification by sandwich ELISA as previously described (Hippenstiel *et al.*, 2000).

Cell transfection and luciferase reporter gene assay

Cells were transfected with pGL3-basic based luciferase reporter gene plasmids NF-κB-Luc (Clontech, Madison, WI, USA) or IL-8prom-Luc (Nourbakhsh *et al.*, 2001). HEK293 cells, and HEK293 cells stably expressing EP₁, EP₄ or both receptors were transfected using a modified calcium phosphate transfection protocol. Twenty hours after transfection, cells were treated with 1 µM PGE₂, 1 µM EP receptor agonists or 50 ng mL⁻¹ TNFα for the time indicated. At the end of the experiment, cells were lysed in 100 µL lysis buffer, and firefly luciferase activity was measured in 25 µL of cell lysate using the Fluostar Optima (BMG Labtech, Offenburg, Germany).

Western blot analysis

HEK293-EP₁ + EP₄ cells were stimulated with 1 µM PGE₂ or EP receptor specific agonist for the time indicated. In some experi-

ments, cells were incubated with 10 µM of the Src kinase inhibitor (4-amino-5-(4-chlorophenyl)-7-(dimethylethyl) pyrazolo[3,4-d]pyrimidine (PP2) for 1 h before agonist stimulation. Cells were lysed in lysis buffer [20 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% (v v⁻¹) Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerolphosphate, 50 mM NaF, protease inhibitors and 1 mM sodium orthovanadate], homogenized by sonication, and insoluble material was removed by centrifugation (10 000× *g*, 15 min, 4°C). Protein content was determined. Proteins were resolved by SDS-PAGE and transferred to a PVDF membrane. Membranes were blocked in 5% non-fat dry milk in 20 mM Tris, 136 mM NaCl and 0.1% (v v⁻¹) Tween (TBS/Tween) for 1 h at room temperature and incubated with the first antibody in TBS/Tween containing 5% BSA overnight at 4°C and a horseradish-peroxidase-conjugated anti-rabbit IgG for 2 h at room temperature. Visualization of immune complexes was performed by using chemoluminescence reagent.

Statistical analysis

Unless otherwise indicated, data were analysed by Student's two sided *t*-test for unpaired samples in either homoscedastic or heteroscedastic mode, as appropriate. The threshold for significance was set at *P* < 0.05.

Results

Characterization of EP₁ or/and EP₄ expressing HEK293 cells

HEK, HEK- EP₁, HEK- EP₄ or HEK- EP₁ + EP₄ cells were cultured for 24 h and then EP receptor mRNA copy numbers were determined by real-time RT-PCR using defined copy numbers of EP receptor/GAPDH containing plasmids for the preparation of standard curves. Untransfected HEK cells expressed all four EP receptor mRNAs at a very low level in the order: EP₁ < EP₃ < EP₂ = EP₄ (Table 2). The absolute copy numbers indicate that untransfected HEK cells express no functional EP₁ or EP₃, but they might express low amounts of functional EP₂ and EP₄. In HEK- EP₁ and HEK- EP₄ cells, the respective EP receptor mRNAs were highly overexpressed. Overexpression of either EP₁ or EP₄ left EP₂ and EP₃ mRNA levels unaffected. The EP₄ mRNA copy number in HEK- EP₄ cells was twice the

Table 2EP receptor mRNA profiles in HEK, HEK-EP₁, HEK-EP₄ and HEK-EP₁ + EP₄ cells

Cells	EP ₁ (EP ₁ mRNA × 1000/GAPDH mRNA)	EP ₂ (EP ₂ mRNA × 1000/GAPDH mRNA)	EP ₃ (EP ₃ mRNA × 1000/GAPDH mRNA)	EP ₄ (EP ₄ mRNA × 1000/GAPDH mRNA)
HEK	0.01 ± 0	0.23 ± 0.14	0.03 ± 0.01	0.20 ± 0.11
HEK-EP ₁	169 ± 51	0.25 ± 0.1	0.03 ± 0.01	0.19 ± 0.05
HEK-EP ₄	0.02 ± 0.01	0.2 ± 0.11	0.01 ± 0	313 ± 91
HEK-EP ₁ + EP ₄	117 ± 55	0.25 ± 0.13	0.01 ± 0	291 ± 135

HEK293 cells stably expressing EP₁, EP₄ or EP₁ + EP₄ were cultured for 24 h. EP receptor mRNA and GAPDH mRNA were measured by real-time RT-qPCR as described in Methods. Plasmids (10²–10⁸ copies) containing EP receptor or GAPDH cDNAs were used for preparing standard curves for the calculation of EP receptor or GAPDH mRNA copy numbers. Data represent the mean ± SEM of at least three independent RNA preparations. EP receptor mRNA contents are expressed as copy number EP receptor mRNA × 1000/copy number GAPDH mRNA.

Table 3Competition of cell surface [³H]-PGE₂-binding by PGE₂ and receptor-specific agonist in HEK, HEK-EP₁, HEK-EP₄ and HEK-EP₁ + EP₄ cells

Cells	Competition of [³ H]-PGE ₂ binding by PGE ₂ (fmol per 10 ⁵ cells)	Competition of [³ H]-PGE ₂ binding by EP ₁ agonist (fmol per 10 ⁵ cells)	Competition of [³ H]-PGE ₂ binding by EP ₄ agonist (fmol per 10 ⁵ cells)
HEK	0.05 ± 0.09	–	–
HEK-EP ₁	3.99 ± 0.71	–	–
HEK-EP ₄	15.76 ± 0.63	–	–
HEK-EP ₁ + EP ₄	6.15 ± 0.41	0.37 ± 0.10	5.81 ± 0.39

HEK, HEK-EP₁, HEK-EP₄ or HEK-EP₁ + EP₄ cells in 24-well plates (1 × 10⁵ cells per well) were incubated with 5 nM [³H]-PGE₂ ± 1 μM of EP receptor-specific agonists for 2 h at 4°C. Non-specific cell surface binding was determined in the presence of 10 μM PGE₂. Unbound ligand was removed, and cell surface bound [³H]-PGE₂ was measured by lysing the cells and counting the radioactivity in the lysate. The [³H]-PGE₂ binding by specific EP receptors was determined by subtracting [³H]-PGE₂ binding in the presence of agonists from specific [³H]-PGE₂ binding. Data represent the mean ± SEM of three independent experiments.

EP₁ mRNA copy number in HEK-EP₁ cells. In HEK-EP₁ + EP₄ cells mRNAs of each individual receptor was similar to the copy number in mono-transgenic cells (Table 2). To verify that up-regulation of EP₁/EP₄ mRNAs resulted in overexpression of functional receptor proteins, cell surface [³H]-PGE₂ binding was measured. In accordance with the low expression level of EP receptor mRNAs, untransfected HEK cells showed only little specific [³H]-PGE₂ binding. (Table 3). By contrast, HEK-EP₁ cells bound about 4 fmol [³H]-PGE₂ per 10⁵ cells (80-fold more than untransfected HEK cells) and HEK-EP₄ about 16 fmol [³H]-PGE₂ per 10⁵ cells (315-fold more than untransfected HEK cells). HEK-EP₁ + EP₄ cells bound about 6 fmol [³H]-PGE₂ per 10⁵ cells; thus, the total number of specific PGE₂ binding sites was 123-fold higher than in untransfected HEK cells. The increase in mRNA levels following double transfection was hence not translated into a similar increase in total PGE₂-binding sites. In addition, competition binding experiments with EP₁ or EP₄ specific agonists in HEK-EP₁ + EP₄ cells revealed that most of the specific [³H]-PGE₂ binding sites consisted of EP₄ (94%) and EP₁ contributed to only a small extent (6%) (Table 3). Nevertheless, the results show that EP₁ and EP₄ were functionally overexpressed in the respective cell lines and that functional EP₄

expression was higher than EP₁ expression in mono-transgenic cells as well as in the double-transgenic cell line.

Induction of IL-8 protein and mRNA synthesis and activation of the IL-8 promoter by PGE₂ in HEK-EP₁ but not in HEK or HEK-EP₄ cells

HEK, HEK-EP₁ and HEK-EP₄ cells were cultured for 20 h in the presence of 1 μM PGE₂ or 50 ng mL⁻¹ TNFα. IL-8 protein in the supernatant of treated cells was quantified by ELISA, and the induction level of IL-8 mRNA was determined by real-time RT-PCR. In HEK and HEK-EP₄ cells PGE₂-stimulation did not change IL-8 protein or mRNA levels, whereas TNFα, a prototypical IL-8-inducing cytokine, induced IL-8 protein (HEK: 21-fold, HEK-EP₄ 24-fold) and IL-8 mRNA (HEK: 20-fold, HEK-EP₄ 21-fold) (Figure 1A and B). In both cell lines, TNFα induced IL-8 mRNA and protein synthesis to a comparable extent. By contrast, stimulation of HEK-EP₁ cells with PGE₂ induced a large increase in IL-8 protein (30-fold) and IL-8 mRNA (61-fold) levels that exceeded that induced by TNFα. An increase in IL-8 mRNA in HEK-EP₁ cells was also observed after stimulation with the EP₁-specific agonist ONO-




Figure 1

PGE₂ induces IL-8 protein and mRNA synthesis and IL-8 promoter activation in HEK-EP₁ but not in HEK or HEK-EP₄ cells. HEK, HEK-EP₁ and HEK-EP₄ cells were stimulated with 1 μM PGE₂ or 50 ng mL⁻¹ TNFα for 20 h. For IL-8 promoter activation studies, cells were transfected with an IL-8 minimal promoter luciferase reporter gene plasmid before stimulation. (A) IL-8 protein: IL-8 released in the medium was measured by ELISA. Data shown are means ± SEM of three independent experiments performed in triplicate. Statistics: Student's *t*-test for unpaired samples. a: significantly higher than control (*P* < 0.05). (B) IL-8 mRNA: IL-8 mRNA content was measured by qPCR as described in the Methods section with GAPDH as reference gene. Data shown are means ± SEM of four independent experiments performed in triplicate. Statistics: Student's *t*-test for unpaired samples. a: significantly higher than control (*P* < 0.05). (C) IL-8 promoter activity: luciferase activity was measured in lysates as described in the Method section. Luciferase activity in control samples of each cell line was set at 100%. Data shown are means ± SEM of three to six independent experiments performed in triplicate. Statistics: Student's *t*-test for unpaired samples. a: significantly higher than control (*P* < 0.05).

DI-004, whereas the EP₄-specific agonist ONO-AE1-329 did not affect IL-8 expression in these cells (not shown). The TNFα-dependent increase was lower than in HEK and HEK-EP₄ cells (IL-8 protein: sixfold, IL-8 mRNA: fivefold). Thus, in stably transfected HEK cells, IL-8 synthesis was efficiently induced by PGE₂ via EP₁ but not via EP₄ receptors. To determine whether PGE₂-stimulated IL-8 mRNA transcription was a consequence of IL-8 promoter activation, HEK, HEK-EP₁ and HEK-EP₄ cells were transfected with a reporter gene construct expressing firefly luciferase under the control of an IL-8 promoter fragment. Sixteen hours after transfection, cells were treated with 1 μM PGE₂ or 50 ng mL⁻¹ TNFα for 20 h. PGE₂ did not activate the IL-8 promoter in HEK cells. It activated the IL-8 promoter only slightly (but not statistically significant) in HEK-EP₄ cells (Figure 1C). By contrast, PGE₂ stimulation of HEK-EP₁ cells led to a pronounced IL-8 promoter activation (14-fold) that exceeded the activation by TNFα (ninefold), which also activated the IL-8 promoter in HEK (10-fold) and HEK-EP₄ cells (fivefold). These results show that despite the sensitivity for TNFα-dependent IL-8 promoter activation observed in all three cell lines, PGE₂-dependent IL-8 promoter activation, as well as IL-8 mRNA and protein induction was dependent on EP₁ expression in HEK-EP₁ cells.

Joint activation of EP₁ and EP₄ is essential for maximal PGE₂-stimulated IL-8 promoter activation and IL-8 mRNA and protein induction in HEK-EP₁ + EP₄ cells

Previous studies with human T-lymphocytes indicated a potential role for EP₄ in the regulation of IL-8 synthesis; however, PGE₂ did not by itself stimulate IL-8 synthesis in HEK cells expressing EP₄ receptors. Therefore, we investigated whether EP₄ receptors modulate the EP₁-dependent induction of IL-8 by PGE₂. Double transgenic HEK-EP₁ + EP₄ cells were created to analyse any potential crosstalk between both EP receptors. In HEK EP₁ + EP₄ cells, PGE₂ induced IL-8 production, IL-8 mRNA and IL-8 promoter activity. A significant induction was observed even after 10 h, whereas maximal activation was observed at around 20 h (Figure 2). In HEK-EP₁ + EP₄ cells, PGE₂ activates both receptors. At 20 h, it induced a 49-fold increase in IL-8 protein and a 39-fold increase in IL-8 mRNA (Figure 3A and B). Activation of EP₁ by an EP₁-specific agonist increased IL-8 mRNA and protein significantly but to a much lesser extent than PGE₂ (IL-8 protein: fourfold, IL-8 mRNA: 12-fold), whereas the EP₄-specific agonist only slightly, but not significantly, increased IL-8 (Figure 3A and B). A robust increase in IL-8 mRNA and protein, which reached the IL-8 mRNA levels stimulated by PGE₂, was achieved when HEK-EP₁ + EP₄ cells were stimulated with both receptor agonists together (IL-8 protein: 19-fold, IL-8 mRNA: 34-fold). These results show that the simultaneous activation of EP₁ and EP₄ receptors was necessary for maximal IL-8 induction by PGE₂. This could also be observed at the IL-8 promoter level. The EP₄ agonist activated the IL-8 promoter slightly but not significantly (3.2-fold), whereas stimulation with the EP₁ agonist led to a strong and significant activation of the IL-8 promoter (6.5-fold) but did not reach the activation levels observed in cells stimulated with PGE₂ (12-fold) (Figure 3C). Stimulation with both agonists




Figure 2

Time-dependence of PGE₂-induced IL-8 protein and mRNA synthesis and IL-8 promoter activation in HEK-EP₁ + EP₄ cells. HEK-EP₁ + EP₄ cells were stimulated with 1 μ M PGE₂ for the times indicated. For IL-8 promoter activation studies, cells were transfected with an IL-8 minimal promoter luciferase reporter gene plasmid before stimulation. (A) IL-8 protein: IL-8 released into the medium was measured by ELISA. (B) IL-8 mRNA: IL-8 mRNA content was measured by qPCR as described in the Methods section with GAPDH as reference gene. (C) IL-8 promoter activity: luciferase activity was measured in lysates as described in the Methods section. Luciferase activity in samples of cells treated with PGE₂ for 20 h was set at 100%. Data shown are means $\pm$ SEM of five independent experiments performed in triplicate. Statistics: Student's *t*-test for unpaired samples. a: significantly higher than control; b: significantly lower than 20 h PGE₂ (*P* < 0.05).

together activated the IL-8 promoter to the same extent as PGE₂ (11-fold). The results show that for maximal activation of the IL-8 promoter and maximal PGE₂-mediated induction of IL-8 expression both EP₁ and EP₄ signal chains needed to be activated.


PGE₂-stimulated IL-8 promoter activation and IL-8 mRNA induction in HEK-EP₁ + EP₄ cells depends on NF- κ B activation

Induction of IL-8 transcription by most stimuli is controlled by the transcription factor NF- κ B. NF- κ B activation is dependent on phosphorylation of I- κ B by IKK complex, which directs I- κ B to ubiquitination and proteasomal degradation. To determine whether NF- κ B activation is involved in PGE₂-stimulated IL-8 induction via EP₁ and EP₄ activation, HEK-EP₁ + EP₄ cells were treated with the IKK inhibitor BMS-34551 at the same time as stimulation with PGE₂. BMS-34551 had no effect on the basal IL-8 mRNA level and IL-8 promoter activity in these cells but completely blocked PGE₂-mediated IL-8 mRNA induction and IL-8 promoter activation (Figure 4A and B). This shows that PGE₂-stimulated IL-8 induction was dependent on NF- κ B activation in HEK-EP₁ + EP₄ cells.

NF- κ B activation by PGE₂-binding to EP₁ and EP₄

As PGE₂-mediated IL-8 promoter activation and IL-8 mRNA induction in HEK-EP₁ + EP₄ cells was dependent on IKK activation, NF- κ B activation by PGE₂ was analysed in HEK, HEK-EP₁, HEK-EP₄ and HEK-EP₁ + EP₄-cells. To this end, cells were transfected with a NF- κ B-luciferase reporter gene plasmid that encodes firefly luciferase under the transcriptional control of an artificial promoter containing multiple NF- κ B binding sites. NF- κ B activation was quantified by measurement of luciferase activity in extracts from cells stimulated with PGE₂ or TNF α for 20 h. PGE₂ did not activate NF- κ B in HEK cells (Figure 5A). By contrast stimulation of HEK cells with TNF α (which activates NF- κ B via TNF α -receptor 2 subtype signal chain) led to a sustained NF- κ B activation (39-fold). In contrast to parental HEK cells, PGE₂ activated NF- κ B reporter activity in HEK-EP₁ cells (13.5-fold). TNF α activated NF- κ B reporter activity in HEK-EP₁ cells 17.9-fold, similar to the activation level induced by PGE₂ (Figure 5A). Stimulation of HEK-EP₄ cells with PGE₂ activated NF- κ B only slightly (threefold), whereas TNF α led to the same strong NF- κ B activation as in untransfected HEK cells (40-fold). Together, the experiments show that PGE₂ can activate NF- κ B via EP₁ and less efficiently via EP₄. This is in contrast to results obtained in HEK-EP₁ + EP₄ cells expressing both receptors, where EP₁ and EP₄ specific agonists activated NF- κ B reporter activity to a comparable extent (EP₁ agonist 10-fold and EP₄ agonist 7.8-fold; Figure 5B). When cells were stimulated with both agonists at the same time, NF- κ B-activation was similar (21-fold) to the activation obtained after PGE₂-stimulation (26-fold). These results led to the hypothesis that simultaneous stimulation of EP₁ and EP₄ led to maximal NF- κ B activation, which causes maximal PGE₂-dependent IL-8 promoter activation as well as IL-8 mRNA and protein induction.

To further corroborate the hypothesis that activation of EP₁ and EP₄ resulted in a direct activation of NF- κ B, the phosphorylation and hence activation of the upstream



kinase, IKK was analysed by employing phosphospecific antibodies. Stimulation of HEK-EP₁ + EP₄ cells with PGE₂ resulted in a rapid and sustained phosphorylation of IKK (Figure 6A); phosphorylation was observed after 5 min and the enzyme remained phosphorylated over the subsequent 30 min. In HEK-EP₁ + EP₄ cells, the receptor subtype specific agonists both increased IKK phosphorylation slightly albeit not significantly (Figure 6B). Only simultaneous stimulation of the cells with both agonists resulted in significant IKK phosphorylation that was similar to that observed after stimulation with PGE₂ (Figure 6B).

NF- κ B was activated by different EP₁/EP₄ signal chains

EP₁ + EP₄ are both GPCRs. The mechanism linking PGE₂ stimulation to NF- κ B activation is currently unknown. To

Figure 3

Simultaneous activation of EP₁ and EP₄ is essential for maximal PGE₂-stimulated IL-8 promoter activation and IL-8 mRNA and protein induction in HEK-EP₁ + EP₄ cells. HEK-EP₁ + EP₄ cells were stimulated with 1 μ M PGE₂ or 1 μ M of the EP receptor specific agonists ONO-DI-004 (EP₁) or ONO-AE1-329 (EP₄) or a combination of both agonists for 20 h. For IL-8 promoter activation studies, cells were transfected with an IL-8 minimal promoter luciferase reporter gene plasmid before stimulation. (A) IL-8 protein: IL-8 released in the medium was measured by ELISA. Data shown are means $\pm$ SEM of three independent experiments performed in triplicate. Statistics: Student's *t*-test for unpaired samples. a: significantly higher than control and b: significantly lower than PGE₂ ($P < 0.05$). (B) IL-8 mRNA: IL-8 mRNA content was measured by qPCR as described in the Methods section with GAPDH as reference gene. Data shown are means $\pm$ SEM of five independent experiments performed in triplicate. Statistics: Student's *t*-test for unpaired samples. a: significantly higher than control and b: significantly lower than PGE₂ ($P < 0.05$). (C) IL-8 promoter activity: luciferase activity was measured in lysates as described in the Methods section. Luciferase activity in control samples of each cell line was set at 100%. Data shown are means $\pm$ SEM of three to six independent experiments performed in triplicate. Statistics: Student's *t*-test for unpaired samples. a: significantly higher than control and b: significantly lower than PGE₂ ($P < 0.05$).

analyse the signal chains involved in NF- κ B activation HEK-EP₁ cells and HEK-EP₁ + EP₄ cells were transfected with the NF- κ B reporter gene plasmid and treated with inhibitors of intracellular signal chains along with PGE₂, EP receptor agonists or TNF α for 20 h before luciferase activity was measured. EP₁ is coupled to an increase in intracellular calcium concentration via activation of the InsP₃ receptor and/or modulating calcium channels (Katoh *et al.*, 1995; Ji *et al.*, 2010). The PLC inhibitor U73122 as well as the Ca²⁺-chelator EGTA and the Ca²⁺/calmodulin-dependent protein kinase II (CaMKII) inhibitor KN-62 significantly reduced PGE₂-dependent NF- κ B activation in HEK-EP₁ cells but did not prevent activation by TNF α (Figure 7). Inhibition of PKC with the PKC inhibitor bisindolylmaleimide (BIM) had no effect on PGE₂ or TNF α -mediated NF- κ B activation in HEK-EP₁ cells. In contrast, NF- κ B activation with the PKC activator PMA was completely inhibited after treatment with BIM (data not shown). These results show that activation of PLC as well as Ca²⁺-signalling, but not PKC, mediate PGE₂-stimulated NF- κ B activation by EP₁. Another signal molecule, which can phosphorylate and therefore activate IKK/NF- κ B, is the tyrosine kinase Src. As Src can be activated by Ca²⁺-signalling via CaMKII, the function of Src in EP₁-mediated NF- κ B activation was analysed. As shown in Figure 7, Src inhibition by the inhibitor PP2 attenuated EP₁ but not TNF α receptor-mediated NF- κ B activation. This confirms the involvement of Src in EP₁-stimulated NF- κ B activation.

EP₄ couples to cAMP increase via Gs. In addition, activated EP₄ can form a complex with β -arrestin, which leads to activation of Src and subsequent activation of PI3K and Akt kinase by transactivation of the EGF receptor (Buchanan *et al.*, 2006). To find out which EP₄ signal chains are involved in PGE₂-mediated NF- κ B-activation, HEK-EP₁ + EP₄ cells were treated with the PKA inhibitor H89, the Src inhibitor PP2 or the PI3K inhibitor wortmannin before stimulation with PGE₂ or EP receptor-specific agonists. Neither the PKA inhibitor




Figure 4

PGE₂-stimulated IL-8 promoter activation and IL-8 mRNA induction in HEK-EP₁ + EP₄ cells depend on NF-κB activation. HEK-EP₁ + EP₄ cells were stimulated with 1 μM PGE₂ in the absence or presence of the I-κB inhibitor BMS-34551 (10 μM) for 20 h. For IL-8 promoter activation studies, cells were transfected with an IL-8 minimal promoter luciferase reporter gene plasmid before stimulation. (A) IL-8 mRNA: IL-8 mRNA content was measured by qPCR as described in the Methods section with GAPDH as reference gene. Data shown are means ± SEM of five independent experiments performed in triplicate. Statistics: Student's *t*-test for unpaired samples. a: significantly higher than control and b: significant lower than PGE₂ (*P* < 0.05). (B) IL-8 promoter activity: luciferase activity was measured in lysates as described in the Methods section. Luciferase activity in control samples of each cell line was set at 100%. Data shown are means ± SEM of three to six independent experiments performed in triplicate. Statistics: Student's *t*-test for unpaired samples. a: significantly higher than control and b: significantly lower than PGE₂ (*P* < 0.05).

H89 nor the PI3K inhibitor wortmannin affected NF-κB activation by PGE₂ or EP receptor-specific agonists (Figure 8). In contrast, treatment of the cells with the Src inhibitor PP2 significantly reduced NF-κB activation by PGE₂ and both EP₁ + EP₄ specific agonists (Figure 8), whereas PP2 did not affect TNFα-induced NF-κB activation (results not shown). This showed that EP₄-mediated activation of NF-κB was not PKA- or PI3K-dependent but was dependent on Src, which is also involved in NF-κB activation by EP₁. PP2 also inhibited the PGE₂-dependent phosphorylation and activation of IKK upstream of the NF-κB activation and the PGE₂-dependent induction of IL-8 mRNA downstream of the NF-κB activation (Figure 9A and B).




Figure 5

PGE₂ binding to EP₁ and EP₄ leads to NF-κB activation. HEK, HEK-EP₁ and HEK-EP₄ cells (A) as well as HEK-EP₁ + EP₄ cells (B) were transfected with a reporter gene plasmid with firefly luciferase under the control of multiple NF-κB binding sites. After 20 h, cells were stimulated with 1 μM PGE₂, 50 ng mL⁻¹ TNFα or 1 μM of EP₁ and EP₄-specific agonists for a further 20 h. Luciferase activity was measured in lysates as described in the Methods section. Luciferase activity in control samples of each cell line was set at 100%. Data shown are means ± SEM of three to six independent experiments performed in triplicate. Statistics: Student's *t*-test for unpaired samples. a: significantly higher than control and b: significantly lower than PGE₂ (*P* < 0.05).

To further analyse the involvement of Src, the activation of Src was determined with antibodies against phosphotyrosine 416, which is phosphorylated upon activation of the enzyme and hence is a marker of Src activation. Although treatment of HEK-EP₁ + EP₄ cells with either EP₁ or EP₄ agonists resulted in a slight but non-significant phosphorylation of Src, the combined administration of EP₁ + EP₄ agonists or stimulation with PGE₂, which activates both receptor subtypes, resulted in similar and significant phosphorylation of Src (Figure 9C).




Figure 6

Requirement of simultaneous activation of EP₁ and EP₄ for maximal short-term activation of I-κB kinase (IKK) in HEK-EP₁ + EP₄ cells. HEK-EP₁ + EP₄ cells were incubated with 1 μM PGE₂ for the times indicated (A) or with 1 μM PGE₂ or receptor-specific agonists (B). Proteins were extracted from cells with SDS sample buffer containing fluoride and vanadate to inhibit phosphatases. Phosphorylated and total IKKs were determined by Western blot using specific antibodies, peroxidase-coupled secondary antibodies and a luminogenic substrate. Band intensity was quantified luminometrically and expressed as ratio between phosphorylated and total protein. Values are means ± SEM of a minimum of three independent experiments. Statistics: Student's *t*-test for unpaired samples: a: significantly higher than unstimulated control cells; b: significantly lower than cells stimulated with PGE₂, *P* < 0.05. Representative blots are shown.




Figure 7

NF-κB activation by EP₁ is dependent on PLC, Ca²⁺ signalling and Src but not on PKC. HEK-EP₁ cells were transfected with a reporter gene plasmid with firefly luciferase under the control of multiple NF-κB binding sites. After 20 h, cells were stimulated with 1 μM PGE₂ or 50 ng mL⁻¹ TNFα in the absence or presence or of the PLC inhibitor U73122 (10 μM), the Ca²⁺ chelator EGTA (2 mM), the CaMKII inhibitor KN-62 (10 μM), the Src kinase inhibitor PP2 (10 μM) or the PKC inhibitor BIM (0.15 μM) for a further 16 h. Luciferase activity was measured in lysates as described in the Methods section. Luciferase activity in control samples of each cell line was set at 100%. Data shown are means ± SEM of three to six independent experiments performed in triplicate. Statistics: Student's *t*-test for unpaired samples. b: significantly lower than naive (*P* < 0.05).

Discussion

The results of the current study show that simultaneous activation of EP₁ + EP₄ signal chains was necessary for PGE₂-induced maximal activation of IL-8 in HEK293 cells. Although EP₁ activation alone was sufficient to induce a significant increase in IL-8, additional activation of EP₄ enhanced the level of IL-8 induced but did not affect IL-8 expression by itself. In contrast to studies describing PGE₂-enhanced IL-8 formation in T-lymphocytes activated by CD3/CD28 antibodies (Caristi *et al.*, 2005), which were independent of NF-κB but dependent on the transcription factor C/EBP homologues protein (CHOP), PGE₂-triggered IL-8 formation in the current study was NF-κB dependent.

Role of EP receptors in PGE₂-stimulated IL-8 induction

Inflammation is characterized by the infiltration of neutrophils, macrophages and lymphocytes into the injured tissue. The chemokine IL-8 is a potent chemoattractant for neutrophils and leukocytes. It was shown that IL-8 is elevated in a number of inflammatory diseases like asthma (Gibson *et al.*, 2001), colitis (Uguccioni *et al.*, 1999) and rheumatoid arthritis (Hwang *et al.*, 2004). IL-8 has been shown to be induced by many different stimuli. TNFα and IL-1β are known as highly potent stimulators of NF-κB-dependent IL-8 expression in various cell types. In addition to IL-8, TNFα and




Figure 8

NF-κB activation by EP₁ and EP₄ is dependent on Src but not on PKA or PI3K. HEK-EP₁ + EP₄ cells were transfected with a reporter gene plasmid with firefly luciferase under the control of multiple NF-κB binding sites. After 20 h, cells were stimulated with 1 μM PGE₂ or EP₁/EP₄-specific agonists in the presence of the Src inhibitor PP2 (10 μM), the PKA inhibitor H89 (10 μM) or the PI3K inhibitor wortmannin (Wort; 0.1 μM) for a further 20 h. Luciferase activity was measured in lysates as described in the Methods section. Luciferase activity in control samples of each cell line was set at 100%. Data shown are means ± SEM of three to six independent experiments performed in triplicate. Statistics: Student's *t*-test for unpaired samples. b: significantly lower than naive (*P* < 0.05).

IL-1β induce COX-2, the key regulatory enzyme in prostanoid synthesis from arachidonic acid (Vlahos and Stewart, 1999). As a consequence, the concentration of prostaglandins, mainly PGE₂, is elevated in inflamed tissues. The actions of PGE₂ are mediated by its binding to four different GPCRs, EP₁-EP₄, which activate different G proteins and signal chains. EP₁ couples to G_q and Ca²⁺-signalling (Ji *et al.*, 2010) whereas EP₂ and EP₄ couple to G_s and EP₃ to G_i (Breyer *et al.*, 2001). The role of PGE₂ in inflammation is controversial. A number of studies have demonstrated anti-inflammatory actions of PGE₂ including suppression of T-cell induction (van der Pouw Kraan *et al.*, 1995) and prevention of natural killer cell activation (Joshi *et al.*, 2001). In human macrophages PGE₂ suppresses LPS-induced formation of the chemokines IL-8, macrophage inflammatory protein (MIP)-1α, MIP-1β and monocyte chemoattractant protein-1 by binding to EP₄ (Takayama *et al.*, 2002). In addition, PGE₂ suppresses TNFα-formation in mouse macrophages in a PKA-dependent manner and inhibits LPS-induced TNFα-formation in mouse Kupffer cells via G_s-coupled EP₂ and EP₄ receptors (Fennekohl *et al.*, 2002; Wall *et al.*, 2009).

In contrast, PGE₂ has been shown to stimulate IL-8 formation in human T-lymphocytes (Caristi *et al.*, 2005), cystic fibrosis airway epithelia cells (Vij *et al.*, 2008) and human colonic epithelial cells (Dey and Chadee, 2008). Interestingly, PGE₂ was also shown to be involved in IL-8 formation induced by the peptide hormone bradykinin in human airway smooth muscle cells. In these cells, the COX inhibitor

indomethacin inhibited bradykinin-stimulated IL-8 formation, whereas exogenous PGE₂ activated the IL-8 promoter and enhanced IL-8 formation (Zhu *et al.*, 2003). In the present study, PGE₂ induced IL-8 formation only in EP₁ but not in EP₄ expressing cells. In HEK-EP₁ + EP₄, stimulation with a specific EP₁ agonist but not an EP₄ agonist activated IL-8 formation, whereas activation of both receptors was necessary for maximal IL-8 formation. The role of the EP₄ receptor, therefore, seems to be to enhance IL-8 formation triggered by EP₁ signal chains rather than to directly activate the induction of IL-8. These results are in line with experiments in T-lymphocytes where activation of both EP₁ and EP₄ was necessary for maximal PGE₂-induced IL-8 formation (Caristi *et al.*, 2005). In other cell types, EP₄ activation alone was found to be sufficient for PGE₂-mediated IL-8 induction. In Caco-2 cells overexpression of EP₄ but not of the EP₂ led to PGE₂-stimulated IL-8 formation (Dey *et al.*, 2009). In addition, stimulation of untransfected Caco-2 cells with an EP₄-specific agonist but not with an EP₂ agonist led to the same significant increase in IL-8 formation as stimulation with PGE₂. The fact that EP₄ activation induced IL-8 expression in Caco-2 but not in HEK293 cells may be due to activation of different signal chains by EP₄ in these cells. In addition to activation of the cAMP signal pathway, EP₄ was reported to signal via the Src-dependent EGF receptor transactivation and subsequent activation of PI3K (Buchanan *et al.*, 2006). Another possibility is that in Caco-2 but not in HEK293 cells PGE₂ may activate the release of IL-8-inducing mediators, whose IL-8-inducing effect may be enhanced by PGE₂-mediated EP₄ activation. Nevertheless, the results of our study clearly demonstrate that PGE₂-mediated IL-8 formation is directly induced by EP₁ signal chains in our experimental system. In contrast to EP₄, which is widely expressed throughout the body, EP₁ is expressed mainly in the colon and kidney. Therefore, PGE₂-stimulated IL-8 formation in EP₁/EP₄ expressing cells in these organs, which trigger inflammatory processes, is quite a likely paradigm.

Targets of EP₁ + EP₄-dependent signal chains in PGE₂-stimulated IL-8 formation

IL-8 expression is mainly regulated on the transcriptional level. A core IL-8 promoter region spanning nucleotides -1 to -133 is essential and sufficient for transcriptional regulation of the gene. The core promoter includes potential binding sites for the transcription factors AP-1, C/EBP and NF-κB (Hoffmann *et al.*, 2002). Whereas the NF-κB site is essential for IL-8 activation by various stimuli in most cell lines, the AP-1 and C/EBP sites are not required for primary induction but for maximal gene expression (Hoffmann *et al.*, 2002). In addition to these three transcription factors, IL-8 induction by PGE₂ in cystic fibrosis cells or T-Lymphocytes was mediated by activation of transcription factor CHOP (Caristi *et al.*, 2005). A CHOP responsive element is located between bases -130 and -137 in the IL-8 promoter, which overlaps with the AP-1 site. Surprisingly, in cystic fibrosis cells and T-cells, PGE₂-stimulated IL-8 formation was independent of NF-κB; the NF-κB inhibitor caffeic acid did not prevent PGE₂-stimulated IL-8 formation. It was also shown in these studies that CHOP binds to the IL-8 promoter after PGE₂ stimulation and that deletion of the CHOP responsive element inhibited PGE₂-stimulated activation of the IL-8 promoter. By contrast, the




Figure 9

Involvement of PGE₂-mediated activation of Src kinase in HEK-EP₁ + EP₄ cells in PGE₂-dependent IL-8 induction. (A) HEK-EP₁ + EP₄ cells were stimulated with 1 μ M PGE₂ in the absence or presence of the Src kinase inhibitor PP2 (10 μ M) for 20 h. IL-8 mRNA content was measured by qPCR as described in the Methods section with GAPDH as reference gene. (B and C): HEK-EP₁ + EP₄ cells were pre-incubated with PP2 (10 μ M) for 1 h and subsequently stimulated with 1 μ M PGE₂ or receptor-specific agonists for 10 min. Proteins were extracted from cells with SDS sample buffer containing fluoride and vanadate to inhibit phosphatases. Phosphorylated and total IKKs (B) or Src kinase (C) were determined by Western blot using specific antibodies, peroxidase-coupled secondary antibodies and a luminogenic substrate. Band intensity was quantified luminometrically and expressed as ratio between phosphorylated and total protein. Values are means $\pm$ SEM of a minimum of three independent experiments. Statistics: Student's *t*-test for unpaired samples a: significantly higher than non-stimulated control cells; b: significant lower than cells stimulated with PGE₂, *P* < 0.05. Representative blots are shown.

results of the present study demonstrated that PGE₂-mediated IL-8 formation by activation of EP₁ + EP₄ were dependent on NF- κ B activation. This conclusion is based on several lines of evidence. Firstly, PGE₂-stimulated activation of the IL-8 promoter as well as IL-8 mRNA induction was completely abol-

ished by the IKK-inhibitor BMS-34551. Secondly, stimulation with PGE₂ increased NF- κ B activity in HEK293 cells overexpressing EP₁ and/or EP₄ but not in untransfected cells. Thirdly, PGE₂ activation of NF- κ B in HEK-EP₁, HEK-EP₄ and HEK-EP₁ + EP₄ cells has the same profile as PGE₂ activation of




Figure 10

Model of PGE₂/EP₁ + EP₄-mediated NF-κB activation and IL-8 induction. PGE₂-bound EP₁ activates PLC and/or Ca²⁺-channels in the plasma membrane by Gq and/or an as yet unknown G protein. This leads to a transient increase in intracellular Ca²⁺, that thereby activates CamKII. CamKII directly or indirectly via tyrosine kinase Src phosphorylates IKKs and signals I-κB degradation. Src-mediated IKK-phosphorylation is also triggered by PGE₂-binding to the Gs-coupled EP₄, which leads to maximal I-κB degradation. The released NF-κB translocates to the nucleus and promotes IL-8 transcription by binding to the IL-8 promoter.

the IL-8 promoter, induction of IL-8 mRNA and IL-8 protein expression. NF-κB and IL-8 induction was predominantly activated by EP₁, whereas stimulation of EP₄ had only a minor effect on NF-κB activation and IL-8 formation. Maximal NF-κB activation as well as IL-8 induction was observed when both receptors were stimulated at the same time in HEK-EP₁ + EP₄ cells.

EP receptor signal chains leading to NF-κB activation

A number of GPCRs have been shown to activate NF-κB. They include receptors for adenosine (Liu and Wong, 2004), bradykinin (Xie *et al.*, 2000) and somatostatin (Liu and Wong, 2005). These receptors activate NF-κB via the regulation of Gi, Gq and Gq-related G proteins like G14 or G16. G protein coupling of EP₁ is controversial. Although EP₁ activation led to a robust increase in Ca²⁺ concentration, there was only a very modest increase in InsP₃ generation. It was, therefore, suggested that EP₁ is not coupled to Gq but to activation of Ca²⁺ channels via an as yet undefined G protein (Katoh *et al.*, 1995). However, Gq coupling of the EP₁ receptor in HEK cells has also been reported (Ji *et al.*, 2010). Our study suggests that both signal chains are involved in PGE₂-stimulated NF-κB activation by EP₁, because NF-κB activation was significantly inhibited by the PLCβ inhibitor U73122, the Ca²⁺-chelator EGTA and the CamKII inhibitor KN-62. Elevation of intracellular calcium concentration can activate IKK activity

through the action of CamKII. The CamKII inhibitor KN-62 blocks IKK/NF-κB activation by the somatostatin receptor sst₂ (Liu and Wong, 2004); however, the exact mechanism by which CamKII regulates IKK activity remains unclear. Compared to the role of CamKII, activation of PKC was not involved in EP₁-mediated NF-κB activation because the specific PKC inhibitor BIM did not alter PGE₂-stimulated NF-κB activity. This differs from the regulation of NF-κB by sst₂ where PKC activation was necessary for agonist-mediated IKK/NF-κB activation. In contrast to the PKC-independent activation of NF-κB by PGE₂, NF-κB activation by the phorbol ester PMA in HEK-EP₁ cells was completely abolished by BIM, showing that PKC-dependent NF-κB activation occurs in these cells and that the inhibitor BIM was functional.

In addition to the identification of PLCβ and CamKII as transducers of EP₁-mediated NF-κB activation, it was shown that inhibition of the tyrosine kinase Src significantly attenuated EP₁-mediated NF-κB activation in HEK-EP₁ and in HEK-EP₁ + EP₄ cells. Src inhibition also blocked EP₄ agonist-stimulated IKK phosphorylation, NF-κB activation and induction of IL-8 mRNA in HEK-EP₁ + EP₄ cells, whereas inhibitors of PKA and PI3K, which have been described as signal transduction targets activated by EP₄, were ineffective. These results indicate a central role for Src in PGE₂-stimulated NF-κB activation. Once activated, Src was shown to associate directly with the IKK complex, leading to IKK phosphorylation, I-κB degradation and NF-κB activation (Lee *et al.*, 2007). Both EP₁ and EP₄ have been demonstrated to be activators of

Src (Tang *et al.*, 2005; Dey *et al.*, 2009). Although activation of Src by EP₁ most likely occurred via activation of PLC β and CaMKII, activation by EP₄ was dependent on the formation of an EP₄/ β -arrestin/Src 'signalosome complex'. Because Src can be activated by both receptors via different signal chains leading to NF- κ B activation, Src might be the signal molecule that links PGE₂-stimulated IL-8 formation induced by EP₁ and to that activated by EP₄ stimulation (Figure 10). Overall, our data indicate that simultaneous stimulation of EP₁ and EP₄ receptors by PGE₂ induces a marked elevation in the expression of IL-8.

Acknowledgement

The excellent technical assistance of Ines Kahnt, Annika Kühn and Doris Stoll is gratefully acknowledged.

Conflict of interest

No conflicts of interests to declare.

References

- Breyer RM, Bagdassarian CK, Myers SA, Breyer MD (2001). Prostanoid receptors: subtypes and signaling. *Annu Rev Pharmacol Toxicol* 41: 661–690.
- Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN (2006). Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. *Proc Natl Acad Sci U S A* 103: 1492–1497.
- Caristi S, Piraino G, Cucinotta M, Valenti A, Loddo S, Teti D (2005). Prostaglandin E₂ induces interleukin-8 gene transcription by activating C/EBP homologous protein in human T lymphocytes. *J Biol Chem* 280: 14433–14442.
- Dey I, Chadee K (2008). Prostaglandin E₂ produced by *Entamoeba histolytica* binds to EP₄ receptors and stimulates interleukin-8 production in human colonic cells. *Infect Immun* 76: 5158–5163.
- Dey I, Giembycz MA, Chadee K (2009). Prostaglandin E(2) couples through EP(4) prostanoid receptors to induce IL-8 production in human colonic epithelial cell lines. *Br J Pharmacol* 156: 475–485.
- Fennekohl A, Sugimoto Y, Segi E, Maruyama T, Ichikawa A, Püschel GP (2002). Contribution of the two Gs-coupled PGE₂-receptors EP₂-receptor and EP₄-receptor to the inhibition by PGE₂ of the LPS-induced TNF α -formation in Kupffer cells from EP₂- or EP₄-receptor-deficient mice. Pivotal role for the EP₄-receptor in wild type Kupffer cells. *J Hepatol* 36: 328–334.
- Fujino H, Xu W, Regan JW (2003). Prostaglandin E₂ induced functional expression of early growth response factor-1 by EP₄, but not EP₂, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. *J Biol Chem* 278: 12151–12156.
- Gibson PG, Simpson JL, Salto N (2001). Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. *Chest* 119: 1329–1336.
- Hall DA, Beresford IJ, Browning C, Giles H (1999). Signalling by CXC-chemokine receptors 1 and 2 expressed in CHO cells: a comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPgammaS binding induced by IL-8 and GROalpha. *Br J Pharmacol* 126: 810–818.
- Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K (1994). Essential involvement of interleukin-8 (IL-8) in acute inflammation. *J Leukoc Biol* 56: 559–564.
- Hippenstiel S, Soeth S, Kellas B, Fuhrmann O, Seybold J, Krüll M *et al.* (2000). Rho proteins and the p38-MAPK pathway are important mediators for LPS-induced interleukin-8 expression in human endothelial cells. *Blood* 95: 3044–3051.
- Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M (2002). Multiple control of interleukin-8 gene expression. *J Leukoc Biol* 72: 847–855.
- Hwang SY, Kim JY, Kim KW, Park MK, Moon Y, Kim WU *et al.* (2004). IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways. *Arthritis Res Ther* 6: 120–128.
- Ji R, Chou CL, Xu W, Chen XB, Woodward DF, Regan JW (2010). EP1 prostanoid receptor coupling to G i/o up-regulates the expression of hypoxia-inducible factor-1 alpha through activation of a phosphoinositide-3 kinase signaling pathway. *Mol Pharmacol* 77: 1025–1036.
- Joshi PC, Zhou X, Cuchens M, Jones Q (2001). Prostaglandin E₂ suppressed IL-15-mediated human NK cell function through down-regulation of common gamma-chain. *J Immunol* 166: 885–889.
- Katoh H, Watabe A, Sugimoto Y, Ichikawa A, Negishi M (1995). Characterization of the signal transduction of prostaglandin E receptor EP1 subtype in cDNA-transfected Chinese hamster ovary cells. *Biochim Biophys Acta* 1244: 41–48.
- Kobashi C, Asamizu S, Ishiki M, Iwata M, Usui I, Yamazaki K *et al.* (2009). Inhibitory effect of IL-8 on insulin action in human adipocytes via MAP kinase pathway. *J Inflamm* 6: 25.
- Lee HS, Moon C, Lee HW, Park EM, Cho MS, Kang JL (2007). Src tyrosine kinases mediate activations of NF-kappaB and integrin signal during lipopolysaccharide-induced acute lung injury. *J Immunol* 179: 7001–7011.
- Liu AM, Wong YH (2004). G16-mediated activation of nuclear factor kappaB by the adenosine A1 receptor involves c-Src, protein kinase C, and ERK signaling. *J Biol Chem* 279: 53196–53204.
- Liu AM, Wong YH (2005). Activation of nuclear factor kappa B by somatostatin type 2 receptor in pancreatic acinar AR42J cells involves G alpha14 and multiple signaling components: a mechanism requiring protein kinase C, calmodulin-dependent kinase II, ERK, and c-Src. *J Biol Chem* 280: 34617–34625.
- Neuschäfer-Rube F, Hermosilla R, Rehwald M, Rönnstrand L, Schüle R, Wernstedt C *et al.* (2004). Identification of a Ser/Thr cluster in the C-terminal domain of the human prostaglandin receptor EP4 that is essential for agonist-induced beta-arrestin1 recruitment but differs from the apparent principal phosphorylation site. *Biochem J* 379: 573–585.
- Nourbakhsh M, Kalble S, Dorrie A, Hauser H, Resch K, Kracht M (2001). The NF-kappa b repressing factor is involved in basal repression and interleukin (IL)-1-induced activation of IL-8 transcription by binding to a conserved NF-kappa b-flanking sequence element. *J Biol Chem* 276: 4501–4508.
- van der Pouw Kraan TC, Boeijs LC, Smeenk RJ, Wijdenes J, Aarden LA (1995). Prostaglandin-E₂ is a potent inhibitor of human interleukin 12 production. *J Exp Med* 181: 775–779.

- Rajakariar R, Yaqoob MM, Gilroy DW (2006). COX-2 in inflammation and resolution. *Mol Interv* 6: 199–207.
- Rodgers HC, Pang L, Holland E, Corbett L, Range S, Knox AJ (2002). Bradykinin increases IL-8 generation in airway epithelial cells via COX-2-derived prostanoids. *Am J Physiol Lung Cell Mol Physiol* 283: L612–L618.
- Roebuck KA (1999). Regulation of interleukin-8 gene expression. *J Interferon Cytokine Res* 19: 429–438.
- Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F *et al.* (2000). The role of prostaglandin E receptor subtypes (EP₁, EP₂, EP₃, and EP₄) in bone resorption: an analysis using specific agonists for the respective EPs. *Endocrinology* 141: 1554–1559.
- Takayama K, García-Cardena G, Sukhova GK, Comander J, Gimbrone MA Jr *et al.* (2002). Prostaglandin E₂ suppresses chemokine production in human macrophages through the EP₄ receptor. *J Biol Chem* 277: 44147–44154.
- Takehara H, Iwamoto J, Mizokami Y, Takahashi K, Ootubo T, Miura S *et al.* (2005). Involvement of cyclooxygenase-2 – prostaglandin E₂ pathway in interleukin-8 production in gastric cancer cells. *Dig Dis Sci* 51: 2188–2197.
- Tang CH, Yang RS, Fu WM (2005). Prostaglandin E₂ stimulates fibronectin expression through EP₁ receptor, phospholipase C, protein kinase C α , and c-Src pathway in primary cultured rat osteoblasts. *J Biol Chem* 280: 22907–22916.
- Uguccioni M, Gionchetti P, Robbiani DF, Rizzello F, Peruzzo S, Campieri M *et al.* (1999). Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. *Am J Pathol* 155: 331–336.
- Vij N, Amoako MO, Mazur S, Zeitlin PL (2008). CHOP transcription factor mediates IL-8 signaling in cystic fibrosis bronchial epithelial cells. *Am J Respir Cell Mol Biol* 38: 176–184.
- Vlahos R, Stewart AG (1999). Interleukin-1 α and tumour necrosis factor- α modulate airway smooth muscle DNA synthesis by induction of cyclo-oxygenase-2: inhibition by dexamethasone and fluticasone propionate. *Br J Pharmacol* 126: 1315–1324.
- Wall EA, Zavzavadjian JR, Chang MS, Randhawa B, Zhu X, Hsueh RC *et al.* (2009). Suppression of LPS-induced TNF- α production in macrophages by cAMP is mediated by PKA-AKAP95-p105. *Sci Signal* 16: 28.
- Waugh DJ, Wilson C (2008). The interleukin-8 pathway in cancer. *Clin Cancer Res* 14: 6735–6741.
- Xie P, Browning DD, Hay N, Mackman N, Ye RD (2000). Activation of NF- κ B by bradykinin through a G α (q)- and G β 2 gamma-dependent pathway that involves phosphoinositide 3-kinase and Akt. *J Biol Chem* 275: 24907–24914.
- Yang YY, Hu CJ, Chang SM, Tai TY, Leu SJ (2004). Aspirin inhibits monocyte chemoattractant protein-1 and interleukin-8 expression in TNF- α stimulated human umbilical vein endothelial cells. *Atherosclerosis* 174: 207–213.
- Zhu YM, Bradbury DA, Pang L, Knox AJ (2003). Transcriptional regulation of interleukin (IL)-8 by bradykinin in human airway smooth muscle cells involves prostanoid-dependent activation of AP-1 and nuclear factor (NF)-IL-6 and prostanoid-independent activation of NF- κ B. *J Biol Chem* 278: 29366–29375.